Daily Briefing for November 11, 2026

FDA adds vision-loss warning to every GLP-1 drug, from Ozempic to Zepbound

The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source.

Read the post and its sources

Get the free email briefing

The Food and Drug Administration on Nov. 9 ordered a warning about nonarteritic anterior ischemic optic neuropathy, a rare cause of sudden vision loss, added to the labels of every GLP-1 receptor agonist.

The change covers semaglutide, tirzepatide, liraglutide, dulaglutide, the oral drug orforglipron and generic exenatide. In a meta-analysis of 126 randomized trials, the agency counted 6.4 cases per 100,000 person-years with the drugs and 3.8 with comparators; in its Sentinel cohort, the hazard ratio against DPP-4 inhibitors was 1.43.

Google Cloud opened a preview of an AI agent that works across hospitals' records and billing systems, with HCA Healthcare, Highmark Health and Northwell Health as launch partners. An international commission began a four-day review of whether the United States still meets the definition of measles elimination, and the FDA warned that connectors on some ventilator breathing tubes can detach.

In this episode

• FDA requires every GLP-1 drug label to warn of NAION, a rare cause of sudden and possibly permanent vision loss in one eye
• Google opens an AI agent that pulls records from Epic and billing systems and preps prior authorizations, with HCA and Northwell signed on
• International experts weigh whether the U.S. has lost measles elimination after 5,182 cases this year
• Breathing-tube connectors can come loose mid-ventilation, FDA warns, as Intersurgical removes 38 lots of its 22 mm tubes
• Four states sue to stop Medicaid work rules that start Jan. 1 and require 80 hours a month to keep coverage
• Escitalopram and duloxetine top 21 antidepressants for sustained response beyond 12 weeks in a 115-trial analysis
• FDA opens a new device class with a robot that removes bladder tumors in one piece through the urethra
• Five more states join the FTC's suit accusing Hims & Hers of sharing patients' health data with Meta and Snap